Supreme Court mifepristone case draws dozens of amicus briefs
This intricate legal battle surrounding the regulation of the abortion medication mifepristone has brought forth a myriad of complex arguments and implications. The Supreme Court’s decision on whether to allow the 5th Circuit’s ruling to stand could have far-reaching consequences for both the FDA’s regulatory authority and the accessibility of abortion services in the United States.
At the heart of the issue lies the question of who holds the power to regulate mifepristone – individual states or the FDA. While states have the legal authority to regulate abortion, the FDA governs the approval and distribution of drugs. The FDA’s decision in 2023 to eliminate the requirement for in-person dispensing of mifepristone opened up avenues for increased access to the medication, particularly through mail orders and telehealth appointments.
The emergency requests made by two mifepristone manufacturers have prompted the Supreme Court to take action on the case. The court could issue a quick decision on the matter or send it back to the 5th Circuit for further review. The outcome of this decision could potentially extend the pause on mail orders beyond the initial deadline of Monday at 5 p.m.
Former FDA leaders, the pharmaceutical industry, and food and drug law scholars have all weighed in on the case through amicus briefs. The former FDA commissioners argued that the FDA’s decision to remove the in-person dispensing requirement was scientifically sound and rooted in evidence-based practices. On the other hand, Louisiana contends that the FDA’s decision violates federal laws and undermines the state’s ability to regulate abortions within its borders.
The industry’s lobbying group, PhRMA, warned that allowing the 5th Circuit’s decision to stand could have detrimental effects on drug development and regulatory processes. They argued that Louisiana’s claims regarding the safety of mifepristone were based on misconceptions about the FDA’s reporting system and could set a dangerous precedent for future drug approvals.
Ultimately, the Supreme Court’s ruling in this case will have significant implications for the FDA’s regulatory authority, state-level abortion regulations, and the accessibility of mifepristone for patients across the country. The decision could shape the landscape of drug regulation and abortion services in the United States for years to come. The Food and Drug Administration (FDA) is set to enforce a new Risk Evaluation and Mitigation Strategy (REMS) to address safety concerns surrounding mifepristone, a medication used for abortions. This move comes in response to a court order that mandates stricter safety measures for the drug. However, due to existing mifepristone labeled under the previous policy, there will be a delay in fully implementing the new rules.
Under the reinstated restrictions, in-person dispensing of mifepristone will be required, but providers can still offer abortion medication virtually and through mail using a misoprostol-only regimen. Misoprostol, originally intended for gastric ulcers, has been found to be safe and effective for inducing abortions.
The Supreme Court may potentially rule on the matter based on the Comstock Act to target abortion medication specifically. This could limit the impact of the decision to mifepristone and be reversible if Congress amends the law.
While voices from both sides of the abortion debate have weighed in on the issue, the FDA and the Trump administration have remained silent on their stance regarding mifepristone regulation. Meanwhile, other legal cases involving mifepristone are on hold pending the FDA’s safety review of the drug, expected to be completed in the fall.
Experts are skeptical that the FDA’s review will support its previous decisions, as federal health officials have cited inadequate consideration in the prior REMS approvals. This review presents an opportunity for the FDA to assert its authority and defend its practices concerning mifepristone.
